The United States will share 60 million doses of AstraZeneca‘s Covid-19 vaccine with other countries as coronavirus cases continue to spike worldwide, a top U.S. official said Monday.
Andy Slavitt, a senior advisor to President Joe Biden’s Covid-19 response team, said the U.S. government will share the AstraZeneca shots, which have not yet been authorized by the Food and Drug Administration for use in the U.S., as they become available.
The move comes as state and local health officials say Covid vaccine supply is beginning to outpace demand in some regions of the U.S.
More than 139 million Americans, or 42.2% of the total U.S. population, have received at least one dose of a Covid-19 vaccine, according to the Centers for Disease Control and Prevention. Roughly 94.7 million people, or 28.5% of the population, are fully vaccinated, according to the CDC.
The rate of Covid vaccinations in the U.S. continued to slide over the weekend, according to CDC data, as the seven-day average of daily shots reported administered fell to 2.8 million on Sunday, the lowest level since late March.
Biden had previously said that he expected the U.S. to share its surplus of vaccine does with other countries.
A day earlier, the Biden administration said that it would immediately make raw materials needed for India’s coronavirus vaccine production available as the country works to counter a surge of Covid-19 infections.
Over the past seven days, India has reported an average of about 321,000 new Covid-19 cases per day, up 50% from a week ago, according to data compiled by Johns Hopkins University. The country is averaging about 2,300 Covid deaths per day, according to the Hopkins data, though media reports indicate the official figure is being understated.
Cases are also surging worldwide. The World Health Organization said earlier this week the number of new cases per week has nearly doubled over the past two months, pushing global infections toward their higest level in the pandemic.
–CNBC’s Nate Rattner contributed to this report.
This is a developing story. Please check back for updates.
